Clinical Trial Update: A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide [Phase 2]

View source ↗

Summary

A completed Phase II trial evaluating a combination regimen of doxorubicin, cyclophosphamide, vindesine, and valproic acid in patients with refractory or relaps…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• VALPROIC ACID (Valproic acid)
• Vindesine (vindesine)

Snippet

Sponsor: European Lung Cancer Working Party | Conditions: Small Cell Lung Carcinoma | Phase 2 | Status: COMPLETED